Skip to main content
. 2014 Apr 15;120(15):2325–2333. doi: 10.1002/cncr.28669

Figure 3.

Figure 3

Plots of the estimated the risk of gastrointestinal stromal tumor (GIST) recurrence after initiation of adjuvant imatinib as a function of the 5-factor risk score. (A) Probability of 3-year and 5-year recurrence-free survival. (B) Examples of calculating the 5-year probability of survival without GIST recurrence with the score value of 0.98 (black arrows) or 2.15 (red arrows).